Express News | Qingdao Haier Biomedical Co., Ltd.: Planning a significant Assets restructuring matter, the company's securities are set to be suspended from trading starting December 23.

BreakingsDec 22 23:18

Express News | Qingdao Haier Biomedical Co., Ltd.: Planning a stock-swap merger with Shanghai RAAS Blood Products. Stocks are suspended.

BreakingsDec 22 15:44

qingdao haier biomedical co., ltd. (688139.SH): did not repurchase shares in November

On December 2, Gelonhui Hai'er Biomedical Co., Ltd. (688139.SH) announced that in November 2024, the company did not pass the Shanghai Stock Exchange trading system to repurchase shares through centralized bidding trading. As of November 30, 2024, the company repurchased a total of 1,387,844 shares of the company through the Shanghai Stock Exchange trading system in a centralized bidding trading manner, accounting for 0.44% of the total share capital of 317,952,508 shares of the company. The highest price for repurchase transactions was 32.31 yuan/share, the lowest price was 24.64 yuan/share, and the total amount paid was RMB 40,435.

Gelonghui FinanceDec 2 16:36

Express News | qingdao haier biomedical co., ltd.: Core technical personnel Zhang Jiangtao retired due to personal age reasons.

BreakingsDec 2 16:02

CITIC Securities: The 'old for new' policy is entering the implementation stage. The medical devices sector is expected to enter a period of high growth in performance.

It is expected that in December and the first quarter of 2025, various provinces will gradually implement the trade-in policy, with relevant hospital tenders starting, and equipment manufacturers are likely to see a large number of trade-in orders in the fourth quarter.

Zhitong FinanceNov 25 15:59

Qingdao Haier Biomedical Co., Ltd. (688139): Overseas projects show initial turning point bullish on the synergy of mergers and acquisitions and the growth momentum of Shenzhen New Industries Biomedical Engineering

Investment highlights: On October 30, 2024, the company released the third quarter report of 2024, with a revenue of 1.782 billion yuan for 2024 Q1-3 (-2.4%, the same below), net profit attributable to the parent

soochow securitiesNov 7 00:00